Sugi Predict

Sugi Predict / Targets / EZH1

EZH1

Histone-lysine N-methyltransferase EZH1 · Q92800 · EZH1 on Sugi Atlas →

12,310 patent compounds predicted against EZH1, 10,219 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2595084 SCHEMBL2595084 0.73 15/20
SCHEMBL2591377 SCHEMBL2591377 1.00 13/20
SCHEMBL2594776 SCHEMBL2594776 0.87 13/20
SCHEMBL9284572 SCHEMBL9284572 0.71 13/20
SCHEMBL2585411 SCHEMBL2585411 0.68 13/20
SCHEMBL2592949 SCHEMBL2592949 0.68 13/20
SCHEMBL2595147 SCHEMBL2595147 0.67 13/20
SCHEMBL2594105 SCHEMBL2594105 0.61 13/20
SCHEMBL2594669 SCHEMBL2594669 0.86 12/20
SCHEMBL2592678 SCHEMBL2592678 0.81 12/20
SCHEMBL2588380 SCHEMBL2588380 0.81 12/20
SCHEMBL2592809 SCHEMBL2592809 0.79 12/20
SCHEMBL2594078 SCHEMBL2594078 0.79 12/20
SCHEMBL2591555 SCHEMBL2591555 0.75 12/20
SCHEMBL2595606 SCHEMBL2595606 0.75 12/20
SCHEMBL2588379 SCHEMBL2588379 0.75 12/20
SCHEMBL2595231 SCHEMBL2595231 0.91 11/20
SCHEMBL2588991 SCHEMBL2588991 0.81 11/20
SCHEMBL2585424 SCHEMBL2585424 0.80 11/20
SCHEMBL2593765 SCHEMBL2593765 0.80 11/20

Clinical trials — most relevant to EZH1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS PHASE1/PHASE2WITHDRAWN
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) PHASE1/PHASE2RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer PHASE1/PHASE2RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Zandelisib + Tazemetostat in R/R Follicular Lymphoma PHASE1/PHASE2WITHDRAWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation PHASE2WITHDRAWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Tazemetostat and Palbociclib With CPX-351for R/R AML PHASE1RECRUITING
Study of ORIC-944 in Patients With Metastatic Prostate Cancer PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
Mechanisms of Immune Deficiency nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EZH1 binder may also engage these)

ProteinNameSimilarity
Q5RDS6 — 1.000 Q5RDS6 →
A7E2Z2 — 1.000 A7E2Z2 →
P70351 — 1.000 P70351 →
Q4V863 — 1.000 Q4V863 →
Q08BS4 — 1.000 Q08BS4 →
Q28D84 — 1.000 Q28D84 →
Q61188 — 1.000 Q61188 →
EZH2 Histone-lysine N-methyltransferase EZH2 1.000 landscape →
Q4R381 — 0.999 Q4R381 →
Q28Z18 — 0.998 Q28Z18 →
Q98SM3 — 0.998 Q98SM3 →
P42124 — 0.998 P42124 →
KMT5B Histone-lysine N-methyltransferase KMT5B 0.996 landscape →
O65312 — 0.996 O65312 →
A6QQR4 — 0.996 A6QQR4 →
Q8C0I4 — 0.995 Q8C0I4 →
F4JZ68 — 0.995 F4JZ68 →
Q8WML3 — 0.994 Q8WML3 →
Q5SVQ0 — 0.994 Q5SVQ0 →
Q5TKR9 — 0.994 Q5TKR9 →
Q8W595 — 0.994 Q8W595 →
KAT6B Histone acetyltransferase KAT6B 0.994 landscape →
Q8BZ21 — 0.994 Q8BZ21 →
Q32KD2 — 0.994 Q32KD2 →
DNMT1 DNA (cytosine-5)-methyltransferase 1 0.994 landscape →
G5EEU2 — 0.994 G5EEU2 →
Q5RJX8 — 0.994 Q5RJX8 →
Q08639 — 0.994 Q08639 →
Q6IV56 — 0.994 Q6IV56 →
Q9C813 — 0.994 Q9C813 →